ArticleBioorganic & medicinal chemistry letters2009
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.
Article in Bioorganic & medicinal chemistry letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Breaking the bonds: targeting protein dimerization for prostate cancer therapy.Endocrinology · 2026Review
- New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.Signal transduction and targeted therapy · 2024Review
- Nilotinib: Disrupting the MYC-MAX Heterocomplex.Bioinformatics and biology insights · 2024Article
- Liquid‒liquid phase separation: roles and implications in future cancer treatment.International journal of biological sciences · 2023Review
- Emerging Implications of Phase Separation in Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Luminescence complementation technology for the identification of MYC:TRRAP inhibitors.Oncotarget · 2021Article
- Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay.Bioorganic & medicinal chemistry · 2021Article
- Article
- Targeting transcription factors in cancer - from undruggable to reality.Nature reviews. Cancer · 2019Review
- Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies.International journal of molecular sciences · 2019Review
- Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.International journal of molecular sciences · 2018Review
- Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding.The Journal of biological chemistry · 2018Article
- Methods of probing the interactions between small molecules and disordered proteins.Cellular and molecular life sciences : CMLS · 2017Review
- Role of MYC in B Cell Lymphomagenesis.Genes · 2017Review
- Small molecule selectively suppresses MYC transcription in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Small-molecule inhibitors of the Myc oncoprotein.Biochimica et biophysica acta · 2015Review
- Binding cavities and druggability of intrinsically disordered proteins.Protein science : a publication of the Protein Society · 2015Article
- Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.Journal of medicinal chemistry · 2015Article
- Integrated analysis of transcription factor, microRNA and LncRNA in an animal model of obliterative bronchiolitis.International journal of clinical and experimental pathology · 2015Article
- Protein-DNA array-based identification of transcription factor activities differentially regulated in obliterative bronchiolitis.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The preparation and evaluation of a series of inhibitors of Myc/Max dimerization and Myc-induced cell transformation are described providing mycmycin-1 (3) and mycmycin-2 (4).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.